Searched for: in-biosketch:true
person:katza13
Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance
Werneburg, Glenn T; Kongnyuy, Michael; Halpern, Daniel M; Salcedo, Jose M; Kosinski, Kaitlin E; Haas, Jonathan A; Schiff, Jeffrey T; Corcoran, Anthony T; Katz, Aaron E
BACKGROUND:Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and compare them with active holistic surveillance (AHS) patients. METHODS:An IRB-approved institutional database was retrospectively reviewed for patients who underwent CK, Cryotherapy, or AHS. Quality of life (QoL) survey responses were collected every three months and the mean function scores were analyzed in yearly intervals over the 4 years post-treatment. RESULTS:279 patients (767 survey sets) were included in the study. There was no difference among groups in urinary function scores. The CyberKnife group had significantly lower bowel habit scores in the early years following treatment (year 2 mean difference: -5.4, P < 0.01) but returned to AHS level scores by year 4. Cryotherapy patients exhibited initially lower, but not statistically significant, bowel function scores, which then improved and approached those of AHS. Both CyberKnife (year 1 mean difference: -26.7, P < 0.001) and Cryotherapy groups (-35.4, P < 0.001) had early lower sexual function scores relative to AHS, but then gradually improved and were not significantly different from AHS by the third year post-treatment. A history of hormonal therapy was associated with a lower sexual function scores relative to those patients who did not receive hormones in both CyberKnife (-18.45, P < 0.01) and Cryotherapy patients (-14.6, P < 0.05). CONCLUSIONS:After initial lower bowel habits and sexual function scores, CyberKnife or Cryotherapy-treated patients had no significant difference in QoL relative to AHS patients. These results highlight the benefit of CyberKnife and Cryotherapy in the management of organ-confined prostate cancer.
PMID: 29217830
ISSN: 1476-5608
CID: 3499132
PSA kinetics following primary focal cryotherapy (hemiablation) in organ-confined prostate cancer patients
Kongnyuy, Michael; Islam, Shahidul; Mbah, Alfred K; Halpern, Daniel M; Werneburg, Glenn T; Kosinski, Kaitlin E; Chen, Connie; Habibian, David J; Schiff, Jeffrey T; Corcoran, Anthony T; Katz, Aaron E
PURPOSE/OBJECTIVE:We aim to evaluate prostate-specific antigen (PSA) trends in post-primary focal cryotherapy (PFC) patients. MATERIALS AND METHODS/METHODS:This was an institutional review board-approved retrospective study of PFC patients from 2010 to 2015. Patients with at least one post-PFC PSA were included in the study. Biochemical recurrence (BCR) was determined using the Phoenix criteria. PSA bounce was also assessed. We analyzed rates of change of PSA over time of post-PFC between BCR and no BCR groups. PSA-derived variables were analyzed as potential predictors of BCR. RESULTS:A total of 104 PFC patients were included in our analysis. Median (range) age and follow-up time were 66 (48-82) years and 19 (6.3-38.6) months, respectively. Four (3.8%) patients experienced PSA bounce. The median percent drop in first post-PFC PSA of 80.0% was not associated with BCR (p = 0.256) and may indicate elimination of the index lesion. The rate of increase of PSA in BCR patients was significantly higher compared to patients who did not recur (median PSA velocity (PSAV): 0.15 vs 0.04 ng/ml/month, p = 0.001). Similar to PSAV (HR 9.570, 95% CI 3.725-24.592, p < 0.0001), PSA nadir ≥ 2 ng/ml [HR (hazard ratio) 1.251, 95% CI 1.100-1.422, p = 0.001] was independently associated with BCR. CONCLUSION/CONCLUSIONS:A significant drop in post-PFC PSA may indicate elimination of the index lesion. Patients who are likely to recur biochemically have a significantly higher PSAV compared to those who do not recur. Nadir PSA of less than 2 ng/ml may be considered the new normal PSA in focal cryotherapy (hemiablation) follow-up.
PMID: 29149380
ISSN: 1433-8726
CID: 3499112
PRIMARY TREATMENT MODALITY FOR PROSTATE CANCER IS ASSOCIATED WITH RISK OF BIOCHEMICAL RECURRENCE FOLLOWING SALVAGE CRYOTHERAPY [Meeting Abstract]
Werneburg, Glenn T.; Salcedo, Jose M.; LeSueur, Amanda L.; Haas, Jonathan A.; Schiff, Jeffrey T.; Corcoran, Anthony T.; Katz, Aaron E.
ISI:000429166601705
ISSN: 0022-5347
CID: 3494352
FOCAL CRYOABLATION IS ASSOCIATED WITH SUPERIOR QUALITY OF LIFE AND NO DIFFERENCE IN DISEASE CONTROL RELATIVE TO TOTAL CRYOABLATION IN PROSTATE CANCER PATIENTS [Meeting Abstract]
Werneburg, Glenn T.; Kongnyuy, Michael; Halpern, Daniel M.; Salcedo, Jose M.; Chen, Connie; LeSueur, Amanda L.; Kosinski, Kaitlin E.; Schiff, Jeffrey T.; Corcoran, Anthony T.; Katz, Aaron E.
ISI:000429166601103
ISSN: 0022-5347
CID: 3494322
COMBINATION OF PSA DENSITY, PROSTATE CANCER ANTIGEN 3 AND PI-RADS IN THE PREDICTION OF PROSTATE CANCER IN INITIAL BIOPSY [Meeting Abstract]
Fazzari, Melissa J.; Salcedo, Jose M.; Gildersleeve, Roy T.; Werneburg, Glenn T.; Le Sueur, Amanda L.; Schiff, Jeffrey T.; Corcoran, Anthony T.; Katz, Aaron E.
ISI:000429166601611
ISSN: 0022-5347
CID: 3494342
INITIAL SCREENING USING PCA3 WITH PSAD IMPROVED PROSTATE CANCER DETECTION [Meeting Abstract]
Fazzari, Melissa J.; Salcedo, Jose M.; Gildersleeve, Roy T.; Werneburg, Glenn T.; Le Sueur, Amanda L.; Schiff, Jeffrey T.; Corcoran, Anthony T.; Katz, Aaron E.
ISI:000429166601605
ISSN: 0022-5347
CID: 3494332
MODERATE MINIMUM TUMOR TEMPERATURE IN CRYOTHERAPY IS ASSOCIATED WITH SUPERIOR QUALITY OF LIFE AND NO DIFFERENCE IN DISEASE CONTROL IN PROSTATE CANCER PATIENTS [Meeting Abstract]
Werneburg, Glenn T.; Kongnyuy, Michael; Halpern, Daniel M.; Salcedo, Jose M.; Chen, Connie; LeSueur, Amanda L.; Kosinski, Kaitlin E.; Schiff, Jeffrey T.; Corcoran, Anthony T.; Katz, Aaron E.
ISI:000429166601100
ISSN: 0022-5347
CID: 3494312
Grade 2+Bladder Toxicity in Patients Receiving SBRT for Prostate Cancer: Incidence and Dosimetric Characterization in a Large Patient Cohort [Meeting Abstract]
Blacksburg, S. R.; Sheu, R.; Demircioglu, G.; Mirza, A.; Carpenter, T. J.; Morgenstern, J.; Witten, M. R.; Mendez, C.; Katz, A. E.; Endres, P.; Oshinsky, G.; Lumerman, J.; Shepard, B.; D'Esposito, R.; Edelman, R.; Gershbaum, M. D.; Nejat, R.; Haas, J. A.
ISI:000447811600228
ISSN: 0360-3016
CID: 3493572
Long-term outcomes after percutaneous renal cryoablation performed with adjunctive techniques
Khan, Faraz; Ho, Andrew M; Jamal, Joseph E; Gershbaum, Meyer D; Katz, Aaron E; Hoffmann, Jason C
OBJECTIVE:To review the technical success of image-guided percutaneous cryoablation of renal masses in difficult anatomic locations using adjunctive techniques to displace critical structures away from the ablation zone, while also reporting longer-term outcomes within this patient population. METHODS:An IRB approved, retrospective analysis of 92 renal masses treated with percutaneous cryoablation revealed 15 cases utilizing adjunctive techniques. Tumor size and distance to adjacent organ before and after adjunctive technique and long-term outcomes were evaluated. RESULTS:The adjunctive techniques used were hydrodissection (n=15) and angioplasty balloon interposition (n=1). Before and after adjunctive technique, median tumor proximity to closest organ was 4mm and 26mm, respectively. All cases had appropriate ablation zones and protection of adjacent critical structures. There is no evidence of recurrence or complication on follow-up (median 51months). CONCLUSIONS:Adjunctive techniques to ablate renal masses in difficult locations provide technical success, safety, and favorable long-term outcomes.
PMID: 29324328
ISSN: 1873-4499
CID: 3002022
Cryosurgery, an alternative treatment option for organ-confined prostate cancer: current beliefs and practice patterns of urologists
Kongnyuy, Michael; Halpern, Daniel M; Kosinski, Kaitlin E; Katz, Aaron E
PURPOSE/OBJECTIVE:We aim to evaluate the current beliefs and practice patterns of urologists in regard to use of cryosurgery for management of PCa. METHODS:An anonymous 13-point survey was designed and sent out to members of the Society of Urologic Oncology (SUO), Endourological Society (ES) and American College of Cryosurgery (ACC). Descriptive statistics and univariate analyses were used to determine variables associated with the use of cryosurgery. RESULTS:Of the 206 responses received [81 (39.2 %) SUO; 106 (51.5 %) ES; 19 (9.2 %) ACC], 83 (40.3 %) performed cryosurgery. The majority of respondents who utilize cryosurgery do so in unilateral (80.3 %) and bilateral (77.6 %) intermediate-risk PCa. Also, users of this technology indicated significant use in primary treatment (>72 %), salvage treatment (>83 %), in patients who prefer cryosurgery (89.9 %) have a life expectancy ≥10 years (65.8 %) and poor erections (74.7 %). The main reason for not utilizing cryosurgery was the lack of technical expertise (56.7 %). A urologist in a non-academic practice setting was 3.2 times more likely to perform cryosurgery compared to a urologist in an academic setting, p = 0.0001. CONCLUSION/CONCLUSIONS:Cryosurgery is increasingly being accepted among urologists. However, the need for large-scale studies as well as randomized clinical trials to further delineate the benefits of cryosurgery and convince the non-users and institutions cannot be overemphasized.
PMID: 27761695
ISSN: 1573-2584
CID: 3510632